MX2023010930A - Bloqueadores de kv1.3. - Google Patents

Bloqueadores de kv1.3.

Info

Publication number
MX2023010930A
MX2023010930A MX2023010930A MX2023010930A MX2023010930A MX 2023010930 A MX2023010930 A MX 2023010930A MX 2023010930 A MX2023010930 A MX 2023010930A MX 2023010930 A MX2023010930 A MX 2023010930A MX 2023010930 A MX2023010930 A MX 2023010930A
Authority
MX
Mexico
Prior art keywords
blockers
making
methods
present
polynucleotides encoding
Prior art date
Application number
MX2023010930A
Other languages
English (en)
Spanish (es)
Inventor
Henrik Fischer Munch
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2023010930A publication Critical patent/MX2023010930A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023010930A 2021-03-23 2022-03-22 Bloqueadores de kv1.3. MX2023010930A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21164384 2021-03-23
EP21213431 2021-12-09
PCT/EP2022/057533 WO2022200374A1 (en) 2021-03-23 2022-03-22 Kv1.3 blockers

Publications (1)

Publication Number Publication Date
MX2023010930A true MX2023010930A (es) 2023-09-28

Family

ID=80952156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010930A MX2023010930A (es) 2021-03-23 2022-03-22 Bloqueadores de kv1.3.

Country Status (12)

Country Link
US (1) US20240182531A1 (enExample)
EP (1) EP4314024A1 (enExample)
JP (1) JP2024511449A (enExample)
KR (1) KR20230159403A (enExample)
AU (1) AU2022245193A1 (enExample)
BR (1) BR112023019022A2 (enExample)
CA (1) CA3208713A1 (enExample)
CL (1) CL2023002590A1 (enExample)
IL (1) IL305219A (enExample)
MX (1) MX2023010930A (enExample)
TW (1) TW202304957A (enExample)
WO (1) WO2022200374A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4604984A1 (en) * 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8429751B2 (en) 2009-03-13 2013-04-23 Trustwave Holdings, Inc. Method and apparatus for phishing and leeching vulnerability detection
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
JP2016527250A (ja) 2013-07-22 2016-09-08 キネタ ワン リミテッド ライアビリティ カンパニーＫｉｎｅｔａ Ｏｎｅ，Ｌｌｃ 毒素系治療用ペプチド及びその医薬組成物の眼科的使用
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
EP4031162A1 (en) * 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers

Also Published As

Publication number Publication date
US20240182531A1 (en) 2024-06-06
CA3208713A1 (en) 2022-09-29
EP4314024A1 (en) 2024-02-07
JP2024511449A (ja) 2024-03-13
CL2023002590A1 (es) 2024-03-15
AU2022245193A1 (en) 2023-09-07
IL305219A (en) 2023-10-01
BR112023019022A2 (pt) 2023-10-17
WO2022200374A1 (en) 2022-09-29
KR20230159403A (ko) 2023-11-21
TW202304957A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022003300A (es) Bloqueadores kv1.3.
JOP20200303A1 (ar) عوامل ربط psma واستخداماتها
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
PH12021553018A1 (en) New egfr inhibitors
PH12021500026A1 (en) Irak degraders and uses thereof
MX2022007981A (es) Derivados de polieter, usos y metodos para hacer los mismos.
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
MX2016013744A (es) Formulaciones de lubricante.
MY201262A (en) Polyether derivatives, uses, and methods of making the same
ZA202002197B (en) Channel and synchronization raster
PH12020550614A1 (en) User terminal and radio communication method
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
MX2023014629A (es) Nuevas formas solidas de (3r)-n-[2-ciano-4-fluoro-3-(3-metil-4-oxo -quinazolin-6-il)oxi-fenil]-3-fluoro-pirrolidin-1-sulfonamida.
MX2024006925A (es) Polipeptidos de il-18 estabilizados y usos de estos.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2025013242A (es) Quinoxalinas sustituidas
MX2024001899A (es) Moduladores del canal de potasio.
CL2023002590A1 (es) Bloqueadores de kv1.3
CA241578S (en) Case
WO2021178976A3 (en) Prenyltransferases and methods of making and use thereof
MX2019008096A (es) Penicilina g acilasas.
MX389364B (es) Penicilina g acilasas